David Hallal
Chief Executive Officer & Chairman, Scholar Rock
David Hallal has served as Chief Executive Officer of Scholar Rock since April 2025. He has served as Chairman of Scholar Rock’s Board of Directors since July 2017. David is a proven 30-year veteran in the biopharmaceutical industry, having grown and operated several successful biotechnology companies.
Previously, he served as Chief Executive Officer & Chairman of ElevateBio, a cell and gene therapy company. Prior to ElevateBio, David spent more than a decade at Alexion Pharmaceuticals as Chief Executive Officer, Chief Operating Officer, and Chief Commercial Officer and played a central role in transforming the company from the pre-commercial stage in 2006 to greater than $3 billion in annual revenues by 2016. As the CEO of Alexion, David transitioned the company from a single product to a multi-product enterprise.
Prior to Alexion, David held commercial leadership positions at biopharmaceutical companies where he launched and expanded the adoption of numerous first-in-class and blockbuster products in hematology, oncology, nephrology, immunology, and ophthalmology, as the Vice President of Sales at OSI Eyetech and at Biogen where he led the immunology sales team. Prior to Biogen, David also held various leadership roles at Amgen.
He also serves as the Chairman of the Board of Directors of ElevateBio, Chairman of the Board of Directors of iTeos Therapeutics SA and as a member of the Board of Directors of Seer Biosciences, Inc. David holds a BA in psychology from the University of New Hampshire.
